Alkermes Plc · NASDAQ:ALKS

Alkermes — Q4 2017 Earnings Presentation

16 slides from Alkermes's earnings presentation, Feb 14, 2018

1. Slide 1: Fourth Quarter and Year-End 2017 Financial Results

   Alkermes® Patient inspired Fourth Quarter and Year-End 2017 Financial Results February 14, 2018

2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Information

   Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: future

3. Slide 3: Fourth Quarter Overview and Recent Events

   Fourth Quarter Overview and Recent Events Financial Results Q4 total revenues increased 29% year-over-year to $275.4M VIVITROL ® net sales increased 22% year-over-year to $75.6M ARISTADA ® net sales increased 64% year-over-year to $28.3M Recognized $28.0M upfront payment related to Biogen collaborat

4. Slide 4: Q4 2017 Revenue Summary

   Q4 2017 Revenue Summary Total Revenues ($M) $300 $275 $250 $225 $200 $175 $150 $125 $100 $75 $50 $25 $0 Q4 2016 $213.5 Q4 2017 $275.4 In millions, except % Q4’17 Q4’16 ∆ Q4’17 VS. Q4’16 Q3’17 ∆ Q4’17 VS. Q3’17 VIVITROL ® ARISTADA ® Manufacturing & Royalty Revenue License Revenue Total Revenue $75.6

5. Slide 5: 2017 Revenue Summary

   2017 Revenue Summary Total Revenues ($M) $1,000 $800 $600 $400 $200 $0 $745.7 2016 $903.4 2017 In millions, except % VIVITROL ® ARISTADA® Manufacturing & Royalty Revenue License Revenue Total Revenue FY2017 $269.3 $93.5 $505.3 $28.0 $903.4 FY 2016 $209.0 $47.2 $487.2 0 $745.7 ∆2017 VS. 2016 29% 98%

6. Slide 6: Growing Revenues From Proprietary Commercial Medicines

   Growing Revenues From Proprietary Commercial Medicines Proprietary Commercial Product Revenues ($M) $120, $100 $80 $60 $40 $20 $0 Q1’16 Q2’16 Q3’16 Q4’16 Q1’17 Q2’17 Q3’17 Q4’17 ARISTADA® aripiprazole lauroxil extended-release injectable suspension 441 mg 662 mg 882 mg 1064 mg VIVITROL® (naltrexone

7. Slide 7: VIVITROL Fourth Quarter Performance

   VIVITROL® Fourth Quarter Performance VIVITROL Quarterly Net Sales ($M) $80 $70 $60 $50 $40 $30 $20 $10 $0 Q1’15 Q2’15 Q3’15 Q4’15 Q1’16 Q2’16 Q3’16 Q4’16 Q1’17 Q2’17 Q3’17 Q4’17 Q4 year-over-year net sales growth of 22% 9% sequential net sales growth compared to Q3’17 Q4 results reflect estimated 46

8. Slide 8: ARISTADA Growing in Volume and Gaining Market Share

   ARISTADA® Growing in Volume and Gaining Market Share ARISTADA Quarterly Net Sales ($M) $30 $25 $20 $15 $10 $5 $0 Q1’16 Q2’16 Q3’16 Q4’16 Q1’17 Q2’17 Q3’17 Q4’17 Sequential unit growth of 15% compared to Q3’17 41.5% gross-to-net deductions ARISTADA market share increased to 24% among new aripiprazole

9. Slide 9: Alkermes: 2018 Financial Expectations

   Alkermes: 2018 Financial Expectations † (in millions, except per share amounts) Financial Expectations for Year Ending Dec. 31, 2018 †Revenues $978 – 1,025 COGS $180 – 190 R&D Expense $415 -–445 SG&A Expense $555 - 585 Amortization of intangibles ~$65 Net Interest Expense ~$10 Income tax expense $0

10. Slide 10: VIVITROL: Confluence of Data, Policy and Funding Being Integrated Into Response to Opioid Crisis

    VIVITROL®: Confluence of Data, Policy and Funding Being Integrated Into Response to Opioid Crisis Data underscore utility of VIVITROL for opioid dependence Results from NIDA’s X:BOT study, comparing extended-release naltrexone (VIVITROL) and buprenorphine-naloxone, were published in The Lancet Data

11. Slide 11: ARISTADA: Focused on Patient-Centered Treatment Options

    ARISTADA®: Focused on Patient-Centered Treatment Options NDA submitted to FDA for Aripiprazole Lauroxil NanoCrystal® Dispersion (ALNCD) for initiation onto ARISTADA PDUFA date of June 30, 2018 New initiation regimen designed to replace need for concomitant three weeks of oral aripiprazole Provides a

12. Slide 12: ALKS 5461 Program

    ALKS 5461 Program Investigational product for adjunctive treatment of major depressive disorder Opioid system modulator with new mechanism of action FDA Fast Track status granted Status Submitted NDA, awaiting assignment of PDUFA target action date Publication of data and comprehensive scientific ed

13. Slide 13: ALKS 3831 Program

    ALKS 3831 Program Novel, oral broad-spectrum antipsychotic drug candidate for the treatment of schizophrenia Designed to provide antipsychotic efficacy of olanzapine and a differentiated safety profile with favorable weight and metabolic properties Status Positive results from ENLIGHTEN-1 pivotal an

14. Slide 14: BIIB098 (Formerly ALKS 8700) Program

    BIIB098 (Formerly ALKS 8700) Program Investigational product for the treatment of relapsing forms of multiple sclerosis License and collaboration agreement with Biogen announced in Q4 2017 Status Long-term safety study ongoing; initial data showing low rates of GI AEs presented at ECTRIMS* Pharmacok

15. Slide 15: ALKS 4230 Program

    ALKS 4230 Program Novel immuno-oncology candidate Designed to selectively activate intermediate-affinity IL-2 receptors to enhance tumor-killing immune cells Status Dose-escalation stage of phase 1 study ongoing Preclinical data presented at the SITC Annual Meeting Data showed that treatment with AL

16. Slide 16: www.alkermes.com

    www.alkermes.com © 2018 Alkermes. All rights reserved

Alkermes — Q4 2017 Earnings Presentation on 6ix